That is because in true capitalism and free enterprise there has to be business failures on a regular basis to have also successful businesses.

But that is why the share of zombie companies are growing and biotech stocks are growing too despite most not providing enough promising data from clinical trials.

Most of the valuations you see that jump for these smaller biotech stocks occur when they actually have a good clinical trial. And, then they are bought out by a bigger biotech.